abciximab

Abciximab is a chimeric human-murine monoclonal antibody fragment (Fab) that acts as a potent inhibitor of platelet aggregation. It works by binding to the Glycoprotein IIb/IIIa receptor (integrin αIIbβ3) on human platelets, thereby preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules necessary for platelet aggregation. Abciximab also binds with similar affinity to the Vitronectin receptor (integrin αvβ3), which is present on platelets, vascular endothelial cells, and smooth muscle cells. This dual action contributes to its antithrombotic effects. The drug is primarily used as an adjunct in percutaneous coronary intervention (PCI) procedures to reduce the risk of cardiac ischemic complications such as heart attack by inhibiting thrombus formation during and after angioplasty[1][2][4][5][6].

Brand names

ReoPro

Other names

abciximab